The Database includes

• All studies (n>10 patients) that evaluate specific treatment options to improve disease outcome
  • RCTs, non-randomized controlled, uncontrolled, and retrospective cohorts
  • Anti-malarial, anti-viral, anti IL-6, etc.
  • All patient characteristics, viral load, biomarkers, efficacy, and safety
• Studies (cohorts>100 patients) that evaluate patient characteristics stratified by outcome (independent of treatment)
  • Death/no death, progression to severe disease/not, hospitalization/not
  • Understand impact of disease and patient characteristics on relative outcome risk
  • Can be applied to adjust for impact of patient population differences for meta-analysis of treatment comparisons
• Studies (n>10 patients) that report the time course of viral load, vital signs, and biomarkers
  • Disease model to facilitate understanding of when and how to treat during course of disease
  • Characterize longitudinal relationship among viral load, biomarkers, vital signs and outcomes
• Certara’s CODEx platform provides online access, filtering and graphical and tabular summarization of data across studies
  • Augmentation of database with standardization of endpoint units, clinical terms, and statistical calculations (i.e. odds-ratios, risk-ratios, mean differences etc.)
  • “Automated” pair-wise meta-analysis

To gain access to the COVID-19 Clinical Outcomes Database, please register below. At this time, the database is available to scientists and researchers at academic institutions, non-profit organizations, and biopharmaceutical companies. There is a nominal fee of $500 for 6 months of access to the database, to cover cost of supporting users on the platform. The database is funded by the COVID-19 Therapeutics Accelerator.